<PAGE>
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934 (Amendment No. )
Filed by the Registrant [X]
Filed by a Party other than the Registrant [_]
Check the appropriate box:
[_] Preliminary Proxy Statement [_] Confidential, for Use of the
Commission Only (as permitted
[X] Definitive Proxy Statement by Rule 14a-6(e)(2))
[_] Definitive Additional Materials
[_] Soliciting Material Pursuant to (S) 240.14a-11(c) or (S) 240.14a-12
INNOVASIVE DEVICES, INC.
------------------------------------------------
(Name of Registrant as Specified In Its Charter)
--Enter Company Name Here--
------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required.
[_] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
(1) Title of each class of securities to which transaction applies:
-------------------------------------------------------------------
(2) Aggregate number of securities to which transaction applies:
-------------------------------------------------------------------
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (set forth the amount on which
the filing fee is calculated and state how it was determined):
-------------------------------------------------------------------
(4) Proposed maximum aggregate value of transaction:
-------------------------------------------------------------------
(5) Total fee paid:
-------------------------------------------------------------------
[_] Fee paid previously with preliminary materials.
[_] Check box if any part of the fee is offset as provided by Exchange
Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee
was paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
-------------------------------------------------------------------
(2) Form, Schedule or Registration Statement No.:
-------------------------------------------------------------------
(3) Filing Party:
-------------------------------------------------------------------
(4) Date Filed:
-------------------------------------------------------------------
<PAGE>
INNOVASIVE DEVICES, INC.
734 Forest Street
Marlboro, Massachusetts 01752-3032
May 11, 1999
Dear Stockholder:
You are cordially invited to attend the Annual Meeting of Stockholders of
Innovasive Devices, Inc. (the "Company"), which will be held on June 9, 1999
at 10:00 A.M., at the offices of the Company, 734 Forest Street, Marlboro,
Massachusetts.
The following Notice of Annual Meeting of Stockholders and Proxy Statement
describe the items to be considered by the stockholders and contain certain
information about the Company and its officers and directors.
Please sign and return the enclosed proxy card as soon as possible in the
envelope provided so that your shares can be voted at the meeting in
accordance with your instructions. Even if you plan to attend the meeting, we
urge you to sign and promptly return the proxy card. You can revoke it at any
time before it is exercised at the meeting or vote your shares personally if
you attend the meeting.
We look forward to seeing you.
Sincerely,
RICHARD D. RANDALL
President and Chief Executive
Officer
<PAGE>
INNOVASIVE DEVICES, INC.
734 Forest Street
Marlboro, Massachusetts 01752-3032
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON JUNE 9, 1999
The Annual Meeting of Stockholders of Innovasive Devices, Inc. (the
"Company") will be held at the offices of the Company, 734 Forest Street,
Marlboro, Massachusetts, on June 9, 1999 at 10:00 A.M., for the following
purposes:
1. To elect two directors, each to serve for a term of three years;
2. To ratify the Board of Directors' selection of PricewaterhouseCoopers
LLP as the Company's independent auditors for the fiscal year ending
December 31, 1999; and
3. To transact such other business as may properly come before the meeting
and any or all adjournments thereof.
Stockholders of record at the close of business on April 16, 1999 will be
entitled to notice of and to vote at the meeting and any adjournments thereof.
By Order of the Board of Directors
ROSLYN G. DAUM
Clerk
Dated: May 11, 1999
WHETHER OR NOT YOU EXPECT TO ATTEND THE MEETING, PLEASE COMPLETE, DATE AND
SIGN THE ENCLOSED PROXY AND MAIL IT PROMPTLY IN THE ENCLOSED RETURN ENVELOPE
IN ORDER THAT YOUR SHARES MAY BE REPRESENTED.
<PAGE>
INNOVASIVE DEVICES, INC.
734 Forest Street
Marlboro, Massachusetts 01752-3032
PROXY STATEMENT FOR
ANNUAL MEETING OF STOCKHOLDERS
This Proxy Statement is furnished to the holders of common stock of
Innovasive Devices, Inc. (hereinafter referred to as the "Company") in
connection with the solicitation of proxies to be voted at the Annual Meeting
of Stockholders to be held on June 9, 1999 and at any adjournment of that
meeting. The enclosed proxy is solicited on behalf of the Board of Directors
of the Company. Each properly signed proxy will be voted in accordance with
the instructions contained therein, and, if no choice is specified, the proxy
will be voted in favor of the proposals set forth in the Notice of Annual
Meeting.
A person giving the enclosed proxy has the power to revoke it at any time
before it is exercised at the meeting, by written notice to the Clerk of the
Company, by sending a later dated proxy, or by revoking it in person at the
meeting.
The approximate date on which this Proxy Statement and the enclosed proxy
will first be sent to stockholders is May 13, 1999. The Company's Annual
Report to Stockholders for the year ended December 31, 1998 is being mailed
together with this Proxy Statement.
Only holders of common stock of record on the stock transfer books of the
Company at the close of business on April 16, 1999 (the "record date") will be
entitled to vote at the meeting. There were 9,207,249 shares of common stock
outstanding and entitled to vote on the record date.
Each share of common stock is entitled to one vote. The affirmative vote of
the holders of a plurality of the shares represented at the meeting, if a
quorum is present, is required for the election of directors.
For purposes of the matters before the Annual Meeting, under the Company's
By-Laws, a quorum consists of a majority of the issued and outstanding shares
entitled to vote on such matters as of the record date. Shares as to which a
nominee (such as a broker holding shares in street name for a beneficial
owner) has no voting authority in respect of such matter will be deemed
represented for quorum purposes but will not be deemed to be voting on such
matters, and therefore will not be counted as negative votes as to such
matters. Votes will be tabulated by the Company's transfer agent subject to
the supervision of persons designated by the Board of Directors as inspectors.
<PAGE>
STOCK OWNERSHIP OF DIRECTORS, NOMINEES, EXECUTIVE OFFICERS
AND PRINCIPAL STOCKHOLDERS
The following table sets forth certain information regarding beneficial
ownership of the Company's common stock as of March 31, 1999 by (a) each
director and nominee for director of the Company, (b) each of the executive
officers named in the Summary Compensation Table below, (c) each person known
by the Company to own beneficially 5% or more of its Common Stock and (d) all
current directors and executive officers as a group. Except as otherwise
indicated, each person has sole investment and voting power with respect to
the shares shown as being beneficially owned by such person, based on
information provided by such owners.
<TABLE>
<CAPTION>
Shares Percentage
Beneficially of
Executive Officers, Directors and Nominees Owned Common Stock
- ------------------------------------------ ------------ ------------
<S> <C> <C>
Richard D. Randall(1)................................ 314,162 3.4%
James V. Barrile(2).................................. 181,111 2.0
Joseph A. Ciffolillo(3).............................. 123,941 1.3
Robert R. Momsen(4).................................. 530,675 5.8
Howard D. Palefsky(5)................................ 8,125 *
Richard B. Caspari(6)................................ 373,989 4.1
Alan Chervitz........................................ 289,087 3.1
David J. Foster(7)................................... 846,436 9.2
Eric L. Bannon(8).................................... 21,667 *
Ricardo J. Simmons................................... 6,000 *
T. Wade Fallin....................................... 103,869 1.1%
<CAPTION>
5% Stockholders
- ---------------
<S> <C> <C>
Cohesion Technologies, Inc........................... 843,936 9.2%
500 Faber Place,
Palo Alto, CA 94303
Entities affiliated with InterWest Partners(9)....... 524,727 5.7
3000 Sand Hill Road, Building 3, Suite 255
Menlo Park, CA 94025
New Enterprise Associates VI, Limited Partnership.... 928,863 10.1
2490 Sand Hill Road
Menlo Park, CA 94025
Robert Fleming, Inc.................................. 462,950 5.0
320 Park Avenue -- 11th Floor
New York, NY 10022
E. Marlowe Goble..................................... 888,839 9.7
P. O. Box 6698
Jackson, WY 83001
All current executive officers and directors as a 2,798,935 30.4%
group (11 persons)(10)..............................
</TABLE>
- --------
* Less than 1.0% of the outstanding Common Stock.
(1) Includes 277,778 shares which Mr. Randall may acquire within 60 days of
March 31, 1999 by exercise of options.
(2) Includes 8,333 shares which Mr. Barrile may acquire within 60 days of
March 31, 1999 by exercise of options.
(3) Includes 93,872 shares held by an investment company of which Mr.
Ciffolillo is the president and 30,069 shares which Mr. Ciffolillo may
acquire within 60 days of March 31, 1999 by exercise of options. Mr.
Ciffolillo may be deemed to share voting and investment power with
respect to the shares held by the investment company. He disclaims
beneficial ownership of such shares except to the extent of his
proportionate interest therein.
2
<PAGE>
(4) Includes 521,363 shares held by InterWest Partners V, L.P. ("IWP") and
3,364 shares held by InterWest Investors V, L.P. ("IWI"). Mr. Momsen is a
general partner of InterWest Management Partners V, L.P., the general
partner of IWP, and a general partner of IWI and accordingly may be
deemed to share voting and investment power with respect to these shares.
Mr. Momsen disclaims beneficial ownership of the shares held by such
entities except to the extent of his proportionate partnership interest
therein. Also includes 5,625 shares Mr. Momsen may acquire within 60 days
of March 31, 1999 by exercise of options.
(5) Includes 5,625 shares which Mr. Palefsky may acquire within 60 days of
March 31, 1999 by exercise of options.
(6) Includes 37,340 shares held by Dr. Caspari's wife, Judith Caspari, and
42,500 shares which Dr. Caspari may acquire within 60 days of March 31,
1999 by exercise of options.
(7) Consists of 843,936 shares held by Cohesion Technologies, Inc.
("Cohesion") and 2,500 shares which Mr. Foster may acquire within 60 days
of March 31, 1999 by exercise of options. Mr. Foster is Chief Executive
Officer of Cohesion and accordingly may be deemed to share voting and
investment power with respect to such shares. Mr. Foster disclaims
beneficial ownership of the shares held by Cohesion.
(8) Consists of shares which Mr. Bannon may acquire within 60 days of March
31, 1999 by exercise of options.
(9) Consists of 521,363 shares held by IWP and 3,364 shares held by IWI.
(10) Includes 1,462,731 shares beneficially owned by entities affiliated with
Messrs. Ciffolillo, McConnell, Momsen and Foster, for which they disclaim
beneficial ownership except to the extent of their proportionate interest
therein. Also includes 394,097 shares which the executive officers and
directors may acquire within 60 days of March 31, 1999 by exercise of
options.
3
<PAGE>
ELECTION OF DIRECTORS
(Item 1 of Notice)
There are currently seven members of the Board of Directors. The Board has
fixed the number of directors for the ensuing year at seven and has nominated
Richard D. Randall and Howard D. Palefsky for re-election to the Board of
Directors. Each of Messrs. Randall and Palefsky have consented to serve, if
elected at the meeting, for a three-year term expiring at the time of the
Annual Meeting in 2002 and when his successor is elected and qualified. The
shares represented by the enclosed proxy will be voted to elect the nominees
unless such authority is withheld by marking the proxy to that effect. The
nominees have agreed to serve, but in the event any becomes unavailable for
any reason, the proxy, unless authority has been withheld as to such nominee,
may be voted for the election of a substitute. The Board of Directors of the
Company unanimously recommends that stockholders of the Company vote FOR the
election of the foregoing nominees.
The following information is furnished with respect to each nominee for
election as a director.
<TABLE>
<CAPTION>
Principal Occupation and Business Experience During Last Five
Name and Age Years;
as of February 26, 1999 Directorships of Public Companies
----------------------- -------------------------------------------------------------
<C> <S>
Richard D. Randall, 47.... Mr. Randall has been President, Chief Executive Officer and a
director of the Company since February 1994. He was employed
by Target Therapeutics, Inc. from June 1989 to January 1994,
during which time he served as President, Chief Executive
Officer and Chairman. Mr. Randall currently serves as a
director of Conceptus, Inc. ("Conceptus"), a company focusing
on products for the gynecology market. He was also acting
President and acting Chief Executive Officer of Conceptus from
December 1992 to July, 1993.
Howard D. Palefsky, 52.... Mr. Palefsky has been a director of the Company since
September 1995. He was Chief Executive Officer of Collagen
Corporation from March 1978 through February 1996 and briefly
served as Chairman of Collagen Corporation's Board. He was a
director of Target Therapeutics, Inc., and is currently
Chairman of the Board of Conceptus, Inc., a company focusing
on products for the gynecology market, and is an investor and
director of other privately held health care companies.
The following table contains similar information about the other directors
of the Company, whose terms do not expire at the 1999 Annual Meeting and who
consequently are not nominees for election in 1999:
<CAPTION>
Principal Occupation and Business Experience During Last Five
Name and Age Years;
as of February 26, 1999 Directorships of Public Companies
----------------------- -------------------------------------------------------------
<C> <S>
Joseph A. Ciffolillo, 60.. Mr. Ciffolillo has been a director of the Company since
February 1994. Now retired, from 1987 to March 1995, he was
Chief Operating Officer of Boston Scientific Corporation
("Boston Scientific"), a manufacturer and marketer of
minimally invasive medical devices. Prior to joining Boston
Scientific, Mr. Ciffolillo served twenty one years with
Johnson and Johnson and as President of Johnson and Johnson
Orthopedic Company from 1978 to 1982. He is also a director of
CompDent Corporation, a dental health maintenance
organization.
</TABLE>
4
<PAGE>
<TABLE>
<CAPTION>
Principal Occupation and Business Experience During Last Five
Name and Age Years;
as of February 26, 1999 Directorships of Public Companies
----------------------- -------------------------------------------------------------
<S> <C>
David J. Foster, 41..... Mr. Foster has been a director of the Company since June 1997.
In December 1997 he was appointed Chief Executive Office of
Cohesion Technologies, Inc. (formerly Collagen Corporation).
In February 1997 he was named Senior Vice President of
Collagen Corporation where he also served as Chief Financial
Officer from 1992 until February 1997. He has been associated
with Collagen Corporation since November 1984. Mr. Foster
serves as a director of CollOptics, Inc. and previously served
as a director of Prograft Medical, Inc and Pharming Holding,
N.V. Mr. Foster serves as the designated director of Cohesion
Technologies, Inc. (formerly Collagen Corporation) which has
the right, pursuant to a Stockholders' Voting Agreement, to
designate one director of the Company for so long as Cohesion
owns at least 5% of the outstanding common stock of the
Company.
Robert R. Momsen, 52.... Mr. Momsen has been a director of the Company since February
1994. He joined InterWest Partners, a venture capital firm, in
1981 and has been a general partner since 1982. He is also a
director of ArthroCare Corporation, a manufacturer of
arthroscopic surgical equipment, COR Therapeutics, Inc., a
developer of cardiovascular pharmaceuticals, Integ, a
developer of blood glucose monitoring devices, Coulter
Pharmaceutical, a developer of cancer pharmaceuticals,
Urologix, a medical device company treating Benign Prostatic
Hyperplasia, ProGenitor, Inc., a biotechnology company in the
field of genomics and several private companies.
Richard B. Caspari, Dr. Caspari has been a director of the Company since June
M.D., 57............... 1997. He has been a partner of Tuckahoe Orthopaedic Associates
since 1973, and the president and a member of the Board of
Directors of Orthopaedic Research of Virginia since 1981. He
is a founding member of the Arthroscopy Association of North
America and served as its president in 1991. From 1984 to 1986
Dr. Caspari was president of Precision Surgical Instruments
Inc., a developer and manufacturer of arthroscopic devices. He
served on the Board of Directors of Arthrotek, a subsidiary of
Biomet from 1991 to 1996, and on the Board of Directors of
Lifenet, Inc., an organ and tissue transplantation non-profit
organization from 1984 to 1999. He currently serves on the
Board of Heloair, Inc., a helicopter charter company.
Alan Chervitz, 37....... Mr. Chervitz has been Executive Vice President, Chief
Operating Officer and a director of the Company since June
1997. He served as President and Chief Executive Officer of
Medicine Lodge, Inc. ("Medicine Lodge") from January 1996 to
June 1997 and as a director from January 1994 to June 1997. He
also served as Executive VP/General Manager of Medicine Lodge
from 1993 to January 1996. Prior to joining Medicine Lodge, he
served as President and Chief Executive Officer of Ortho
Dynamics, Inc. from August 1989 through December 1993. Mr.
Chervitz also served as a director of Medisys Technologies,
Inc. from January 1992 through 1996.
</TABLE>
BOARD OF DIRECTORS AND COMMITTEE MEETINGS
The Board of Directors has Audit and Compensation Committees. It does not
have a nominating or similar committee.
The Audit Committee, which periodically meets with management and the
Company's independent accountants, reviews the results and scope of the audit
and other services provided by the Company's
5
<PAGE>
independent accountants, the need for internal auditing procedures and the
adequacy of internal controls. The directors currently serving on the Audit
Committee are Messrs. Foster and Palefsky. The Audit Committee met once during
fiscal 1998.
The Compensation Committee establishes salaries for officers and incentives
and other forms of compensation for officers and other key employees;
administers the various incentive compensation and benefit plans; and
recommends policies relating to such plans. The directors currently serving on
the Compensation Committee are Messrs. Ciffolillo and Momsen. The Compensation
Committee met three times during fiscal 1998.
During fiscal 1998, the Board of Directors of the Company held five
meetings. Each incumbent director attended at least 75% of the aggregate
number of the meetings of the Board and the meetings of the committees of the
Board on which he served.
DIRECTOR COMPENSATION
The Company's directors may be reimbursed for certain expenses in connection
with attendance at Board and committee meetings. Under the Company's 1996 Non-
Employee Director Stock Option Plan each non-employee director serving as such
on the date of the Annual Meeting of the Board of Directors is entitled to
receive on such date an option to purchase 2,500 shares of Common Stock
(subject to vesting over four annual periods), exercisable at a price per
share equal to fair market value on the date of grant. Any non-employee
director, upon his or her first election to the Board of Directors, is
entitled to receive an option to purchase 10,000 shares of Common Stock. In
1998, Messrs. Ciffolillo, Palefsky and Caspari each received $15,000 as a
consulting fee in consideration for their service on the Board.
COMPENSATION COMMITTEE REPORT ON EXECUTIVE COMPENSATION
This report, prepared by the Compensation Committee of the Company's Board
of Directors (the "Committee"), addresses the Company's executive compensation
policies and the basis on which fiscal 1998 executive officer compensation
determinations were made. The Committee designs and approves all components of
executive pay.
To ensure that executive compensation is designed and administered in an
objective manner, the Committee's members are all non-employee directors.
During fiscal 1998, the Committee members were Messrs. Ciffolillo and Momsen.
Compensation Philosophy
The Company's executive compensation policies are intended to attract,
retain, motivate and reward executives who can lead the Company in achieving
its long-term growth and earnings goals. The objective of the Committee is to
implement a compensation program that will provide appropriate incentives
while, at the same time, encouraging executive officers to increase their
equity ownership in the Company and thereby align their interests with those
of the Company's stockholders. The compensation program consists primarily of
three components, namely (a) base salary, (b) bonus and (c) stock options.
Each of these factors are further described below. In addition, executive
officers are eligible to participate, on a non- discriminatory basis, in
various benefit programs provided to all full-time employees, including the
Company's stock purchase plan, 401(k) plan and group medical, disability and
life insurance programs. The Committee believes that executive compensation
packages should be viewed as a whole in order to assess properly their
appropriateness.
In establishing total compensation packages for the Company's executive
officers, the Committee takes into account the compensation packages offered
to executives of other medical device design and manufacturing companies of
similar stature. The Committee uses this comparative data primarily as
benchmarks to ensure that
6
<PAGE>
the Company's executive compensation packages are competitive. The Committee
seeks to maintain total compensation within the broad middle range of
comparative pay. The Committee generally meets quarterly and at other times
that it deems are necessary and, from time to time, confers with outside
advisors concerning acceptable industry practices. Individual amounts are
based not only on comparative data, but also on such factors as length of
service with the Company and the Committee's judgment as to individual
contributions. These factors are not assigned specific mathematical weights.
Salary
Base salaries are reviewed annually. It is the Committee's intention to pay
slightly below-market base salary but provide a significant equity ownership
opportunity to create incentives for the Company's executive officers to
maximize the Company's growth and success while increasing stockholders' value
over the long term. Changes in base salary from year to year depend upon such
factors as individual performance, cost of living changes and the economic and
business conditions affecting the Company.
Bonus
Executive bonuses are determined in accordance with achievement of the
Company's goals for the most recent fiscal year. The amounts are intended to
reward management for achieving certain milestones set out at the beginning of
the fiscal year. Among these are growth in operating profit, sales and
earnings. The cash bonus for the Chief Executive Officer is also influenced by
his ability to execute strategic plans determined by the Board of Directors,
including merger and acquisition programs.
Stock Options
As noted above, stock options are an important component of total executive
compensation. Stock options are considered long-term incentives that link the
long-term interests of management with those of the Company's stockholders.
Stock options that the Committee has granted to executive employees generally
vest over a four year period from the date of grant at the rate of 25% per
fiscal year, commencing at the end of the year in which they are granted. The
Committee also granted in 1998 a special option to sales employees, including
certain executive marketing and sales officers of the Company, which were
exercisable only after five years unless the individual sales targets of the
recipients were achieved, in which case the exercisability of the options
would accelerate to the standard four-year vesting schedule for sales
employees (20% after the first and second year and 30% after the third and
fourth year). The 1998 sales targets of the executive officers of the Company
to whom these special options were granted were not achieved, so the options
granted to such officers are not exercisable until 2008. Option exercise
prices are set at 100% of the fair market value of the stock at the date of
the grant and expire after ten years. The Committee has absolute discretion to
determine the recipients and the number of options to be awarded. Each award
is at the Committee's discretion and is not subject to any specific formula or
criteria. The Committee generally awards options on an annual basis. The
number of shares for which options were granted to executive officers in
fiscal 1998 was determined by the Committee based upon several factors,
including the executive's position, his or her past and future expected
performance, the comparative data described above, and the number of shares
under options previously granted. These factors were evaluated in a
qualitative manner and were not assigned predetermined weights.
Stock Option Repricing
During fiscal 1998, certain stock options granted to executive officers and
others on February 4, 1997 and December 10, 1997 at an exercise price of
$10.13 and $8.75 per share, respectively, were canceled and reissued on
December 14, 1998 at a new exercise price of $3.25. The vesting terms of the
reissued options were reset to begin vesting in four annual installments from
December 14, 1998. The Committee considers equity ownership interests to be an
important component of the compensation of executive officers as a way to
reward performance and to provide appropriate incentives for long term growth
and profitability.
7
<PAGE>
The following table is provided regarding repricing of options in fiscal
1998 for the Company's executive officers:
Ten Year Option Repricing
<TABLE>
<CAPTION>
Number of
Securities Length of Original
Underlying Market Price of New Option Term
Options Stock at Time of Exercise Remaining at Date
Name Date of Repricing Repriced Repricing Price of Repricing
---- ----------------- ---------- ---------------- -------- ------------------
<S> <C> <C> <C> <C> <C>
Richard D. Randall...... 12/14/98 25,000 $3.25 $3.25 8.1 years
36,000 3.25 3.25 9.0 years
James V. Barrile........ 12/14/98 25,000 3.25 3.25 8.1 years
26,000 3.25 3.25 9.0 years
Eric L. Bannon.......... 12/14/98 15,000 3.25 3.25 8.1 years
16,000 3.25 3.25 9.0 years
Ricardo J. Simmons...... 12/14/98 60,000 3.25 3.25 8.8 years
Alan Chervitz........... 12/14/98 35,000 3.25 3.25 8.5 years
26,000 3.25 3.25 9.0 years
T. Wade Fallin.......... 12/14/98 25,000 3.25 3.25 8.5 years
16,000 3.25 3.25 9.0 years
</TABLE>
Compensation of Richard D. Randall, President and Chief Executive Officer
During 1998, the compensation of Mr. Randall was determined by applying the
same criteria discussed in this report used to determine salaries, bonuses and
stock option grants for all executive officers. Mr. Randall's compensation for
1998 is set forth in the Summary Compensation Table appearing on page 10.
Section 162(m)
Section 162(m) of the Internal Revenue Code which became effective January
1, 1994, generally limits the deductibility of annual compensation for certain
officers to $1 million. It is the general intention of the Committee to assure
that officer compensation will meet the Section 162(m) requirements for
deductibility. However, the Committee reserves the right to use its judgment
to authorize compensation payments which may be in excess of the limit when
the Committee believes such payment is appropriate, after taking into
consideration changing business conditions or the officer's performance, and
is in the best interest of the shareholders. The Committee will review its
policy concerning Section 162(m) on a year-by-year basis.
Compensation Committee
Joseph A. Ciffolillo
Robert R. Momsen
8
<PAGE>
COMPARISON OF CUMULATIVE TOTAL STOCKHOLDER RETURN
The following performance graph assumes an investment of $100 on June 7,
1996 (the day following the date the Company's common stock was first
registered under Section 12 of the Securities Exchange Act of 1934) and
compares the changes thereafter in the market price of the Company's common
stock with a broad market index (Nasdaq Stock Market) and an industry index
(Standard & Poor's Health Care--Medical Products). The Company paid no
dividends during the periods shown; the performance of the indexes is shown on
a total return (dividend reinvestment) basis. The graph lines merely connect
the initial public offering date and the fiscal year-end dates and do not
reflect fluctuations between those dates.
Research Data Group Peer Group Total Return Worksheet
Innovasive Devices Inc (IDEA)
Cumulative Total Return
---------------------------
6/7/96 12/96 12/97 12/98
INNOVASIVE DEVICES, INC. 100 62 73 27
NASDAQ STOCK MARKET (U.S.) 100 113 139 196
S & P HEALTH CARE (MEDICAL PRODUCTS & SUPPLIES) 100 113 141 203
The Compensation Committee Report on Executive Compensation and the
Comparison of Cumulative Total Stockholder Return information above shall not
be deemed "soliciting material" or incorporated by reference into any of the
Company's filings with the Securities and Exchange Commission by implication
or by any reference in any such filing to this Proxy Statement.
9
<PAGE>
EXECUTIVE OFFICER COMPENSATION
The following summary compensation table sets forth the compensation paid or
accrued for services rendered in fiscal 1998, 1997 and 1996 to the chief
executive officer and the other four most highly compensated executive
officers of the Company (the "Named Executive Officers").
Summary Compensation Table
<TABLE>
<CAPTION>
Long-Term
Compensation
Annual Compensation Awards
-------------------------------- --------------
Other Annual Securities All Other
Name and Fiscal Bonus(s) Compensation Underlying Compensation
Principal Position Year Salary ($) ($) ($) Options (#)(2) ($)(1)
------------------ ------ ---------- -------- ------------ -------------- ------------
<S> <C> <C> <C> <C> <C> <C>
Richard D. Randall ..... 1998 198,725 40,000 -- 61,000 313
President and Chief 1997 174,807 35,000 -- 61,000 193
Executive Officer 1996 170,096 35,000 -- 44,444 195
Eric L. Bannon.......... 1998 125,000 20,000 -- 31,000 92
Vice President, Quality 1997 98,708 25,000 -- 31,000 138
Assurance and Regulatory
Affairs 1996 95,909 -- -- 6,667 53
James V. Barrile........ 1998 149,239 30,000 -- 51,000 184
Executive Vice Presi-
dent, 1997 133,615 25,000 -- 51,000 193
and Chief Financial Of-
ficer 1996 122,212 25,000 -- 11,111 167
Alan Chervitz........... 1998 149,157 30,000 -- 61,000 119
Executive Vice President 1997 56,237 -- -- 61,000 97
and Chief Operating
Officer
Ricardo J. Simmons...... 1998 124,941 5,000 60,000 59
Vice President--Global 1997 23,077 -- -- 60,000 --
Sales and Marketing
T. Wade Fallin.......... 1998 124,349 17,500 -- 41,000 119
Vice President and Gen-
eral Manager 1997 53,383 -- -- 41,000 63
</TABLE>
- --------
(1) The amounts indicated under "All Other Compensation" indicate annual
contributions by the Company towards group term life insurance for the
Named Executive Officers. These amounts are included as reportable income
in each individual's Form W-2.
(2) The awards set forth in 1998 for each Named Executive Officer represent
options canceled and reissued on the terms discussed in the Compensation
Committee Report on Executive Compensation. Other than such repriced
options, no new options were granted to the Named Executive Officers in
1998.
10
<PAGE>
Options Grants In Last Fiscal Year
On December 14, 1998, the Company elected to grant certain executive
officers with outstanding stock options the opportunity to cancel their
existing options and receive new options on a one for one basis with a four
year vesting schedule commencing on the new date of grant. Information related
to the grant of these options is contained in the Compensation Committee's
report on Executive Compensation.
<TABLE>
<CAPTION>
Potential
Realizable Value
at Assumed Annual
Rate of Stock
Price
Appreciation for
Option Term
-----------------
Percent of Total Exercise
Number of Shares Options Granted Price
Underlying Options to Employees in per Expiration
Name Granted Fiscal Year Share Date 5% 10%
---- ------------------ ---------------- -------- ---------- -------- --------
<S> <C> <C> <C> <C> <C> <C>
Richard D. Randall...... 61,000 7% $3.25 12/14/08 $124,678 $315,959
James V. Barrile........ 51,000 6% 3.25 12/14/08 104,239 264,163
Alan Chervitz........... 61,000 7% 3.25 12/14/08 124,678 315,959
Ricardo J. Simmons...... 60,000 7% 3.25 12/14/08 122,634 310,780
Eric L. Bannon.......... 31,000 4% 3.25 12/14/08 63,361 160,570
T. Wade Fallin.......... 41,000 5% 3.25 12/14/08 83,800 212,366
Fiscal Year-End Option Values
The following table sets forth information regarding the number of options
exercised in fiscal 1998 and the number of vested and unvested options and the
unrealized value or spread (the difference between the exercise price and the
market value) of the unexercised options issued by the Company and held by the
Named Executive Officers on December 31, 1998.
<CAPTION>
Number of Shares Value of
Underlying Unexercised
Unexercised In-the-
Options(#) Money Options($)
------------------- -----------------
Shares
Acquired on Value
Name Exercise (#) Realized Vested Unvested Vested Unvested
---- ------------------ ---------------- -------- ---------- -------- --------
<S> <C> <C> <C> <C> <C> <C>
Richard D. Randall...... -- -- 266,667 83,222 $411,890 $ 7,625
James V. Barrile........ -- -- 5,555 56,556 -- 6,375
Eric L. Bannon.......... -- -- 20,000 35,445 28,084 5,747
Ricardo J. Simmons...... -- -- -- 60,000 -- 7,500
Alan Chervitz........... -- -- -- 61,000 -- 7,625
T. Wade Fallin.......... -- -- -- 41,000 -- 5,125
</TABLE>
Change of Control Arrangements
As of April 6, 1999, the Company and each of the Named Executive Officers
entered into Income Continuation Agreements. If upon a change of control of
the Company or during the twelve month period thereafter, the employment of
one of these employees is terminated without cause or if such employee
terminates his employment with the Company as a result of a diminution in job
responsibility or as a result of a relocation, the affected employee is
entitled to severance payments and an acceleration of his options. The
severance payments will equal one year's salary plus incentive compensation if
the employee's service with the Company is less than three years as of the
termination date, and to two years' salary plus incentive compensation if the
employee's service with the Company is three years or more as of the
termination date. The employee will also be entitled to a continuation of
health benefits and insurance coverage during the period that severance will
be paid. The Income Continuation Agreements also provide that 50% of the
options held by such employees as of the date of a change of control shall
become exercisable immediately prior to the change of control, with the
balance becoming exercisable no later than one year thereafter. However, if,
upon a change of control of the Company or during the twelve month period
thereafter, the employment of one of these employees is terminated without
cause or if such employee terminates his employment with the Company as a
result of a diminution in job responsibility or as a result of a relocation,
all outstanding options held by an affected employee shall become exercisable
and shall remain exercisable for 90 days following the date of termination. If
it is determined that the amount payable to an employee on or as a result of a
change of control would cause the payment to be subject to the excise tax
imposed by Section 4999 of the Internal Revenue Code or would constitute an
excess parachute payment under Section 280G of the Internal Revenue Code, the
severance payments will be cut back to be $1.00 less than the amount which
would subject the payment to such excise tax or treatment.
11
<PAGE>
RATIFICATION OF SELECTION OF
INDEPENDENT AUDITORS
(Item 2 of Notice)
On the recommendation of the Audit Committee, the Board of Directors has
selected PricewaterhouseCoopers LLP, independent certified public accountants,
as auditors of the Company for the fiscal year ending December 31, 1999. This
firm has audited the accounts and records of the Company since 1991. A
representative of PricewaterhouseCoopers LLP will be present at the Annual
Meeting to answer questions from stockholders and will have an opportunity to
make a statement if desired.
The selection of independent auditors is not required to be submitted to a
vote of the stockholders. The Board believes, however, it is appropriate as a
matter of policy to request that the stockholders ratify the appointment. If
the stockholders do not ratify the appointment, the Board will reconsider its
selection.
SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Section 16(a) of the Securities Exchange Act of 1934, as amended (the "1934
Act"), requires the Company's officers and directors and persons who own more
than ten percent of its common stock to file reports with the Securities and
Exchange Commission disclosing their ownership of stock in the Company and
changes in such ownership. Copies of such reports are also required to be
furnished to the Company. Based solely on a review of the copies of such
reports received by it, the Company believes that, during fiscal 1998, all
such filing requirements were complied with.
STOCKHOLDER PROPOSALS FOR 2000 MEETING
Proposals of stockholders intended to be presented at the 2000 Annual
Meeting of Stockholders must be presented on or before January 14, 2000 for
inclusion in the proxy materials relating to that meeting. Any such proposals
should be sent to the Company at its principal offices addressed to the Vice
President, Finance and Administration. Other requirements for inclusion are
set forth in Rule 14a-8 under the 1934 Act. In addition, if the Company
receives notice of a stockholder proposal after April 1, 2000, the persons
named as proxies for the 2000 Annual Meeting will have discretionary authority
to vote upon such proposal.
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The following documents filed with the Commission by the Company (File No.
0-28492) pursuant to the Exchange Act are incorporated by reference in this
Proxy statement.
1. The Company's Annual Report on Form 10-K for the fiscal year ended
December 31, 1998 (including all audited financial statements contained
therein);
2. The Company's Annual Report to Stockholders for the fiscal year ended
December 31, 1998 (including all audited financial statements contained
therein);
3. The Company's Current Report on Form 8-K dated July 23, 1996; and
4. The Company's Registration Statement on Form S-1 (Registration No.
333-3368) filed with the SEC on May 17, 1996.
This Proxy Statement incorporates documents by reference which are not
presented herein or delivered herewith. Such documents (other than exhibits or
schedules to such documents unless such exhibits or documents are specifically
incorporated herein by reference) are available to any person, including any
beneficial owner, to whom this Proxy Statement is delivered, on written or
oral request, without charge, directed to Innovasive Devices, Inc., 734 Forest
Street, Marlboro, Massachusetts 01752-3032, Attention: Chief Financial Officer
(telephone number: (508) 460-8229).
12
<PAGE>
OTHER MATTERS
The Company has no knowledge of any matters to be presented for action by
the stockholders at the Annual Meeting other than as set forth above. However,
the enclosed proxy gives discretionary authority to the persons named therein
to act in accordance with their best judgment in the event that any additional
matters should be presented.
The Company will bear the cost of the solicitation of proxies by management,
including the charges and expenses of brokerage firms and others for
forwarding solicitation material to beneficial owners of common stock.
By order of the Board of Directors
Roslyn G. Daum
Clerk
May 11, 1999
The Board hopes that stockholders will attend the meeting. WHETHER OR NOT
YOU PLAN TO ATTEND, YOU ARE URGED TO COMPLETE, DATE, SIGN AND RETURN THE
ENCLOSED PROXY IN THE ACCOMPANYING ENVELOPE. A prompt response will greatly
facilitate arrangements for the meeting, and your cooperation will be
appreciated. Stockholders who attend the meeting may vote their stock
personally even though they have sent in their proxies.
13
<PAGE>
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS
INNOVASIVE DEVICES, INC.
1999 ANNUAL MEETING OF STOCK HOLDERS
The undersigned stockholder of INNOVASIVE DEVICES, INC., a Massachusetts
corporation, hereby acknowledges receipt of the Notice of Annual Meeting of
Stockholders and related Proxy Statement, and hereby appoints Richard D. Randall
and James V. Barille, or any one of them, proxies and attorneys-in-fact, with
full power to each of substitution, on behalf and in the name of the
undersigned, to represent the undersigned at the 1999 Annual Meeting of
Stockholders of INNOVASIVE DEVICES, INC. to be held on Wednesday, June 9, 1999
at 10:00 a.m., local time, at Company Headquarters, 734 Forest Street, Marlboro,
Massachusetts, and at any adjournment(s) thereof , and to vote all shares of
Common Stock which the undersigned would be entitled to vote if then and there
personally present, on the matters set forth on the reverse side.
THIS PROXY WILL BE VOTED AS DIRECTED OR, IF NO CONTRARY DIRECTION IS INDICATED,
WILL BE VOTED FOR THE ELECTION OF DIRECTORS, FOR THE RATIFICATION OF THE
APPOINTMENT OF PRICEWATERHOUSECOOPERS LLP AS INDEPENDENT AUDITORS, AND AS SAID
PROXIES DEEM ADVISABLE ON SUCH OTHER MATTERS AS MAY COME BEFORE THE MEETING.
- -------------------- --------------------
SEE REVERSE CONTINUE AND TO BE SIGNED ON SEE REVERSE
SIDE REVERSE SIDE SIDE
- -------------------- --------------------
<PAGE>
[1631 -INNOVASIVE DEVICES, INC.] [FILE NAME: INN64.ELX] [VERSION -2] [4/23/99]
DETACH HERE
- --------------------------------------------------------------------------------
[ X ] Please mark
votes as in
this example.
1. ELECTION OF DIRECTORS
Nominees: Richard D. Randall and Howard D. Palefsky
FOR WITHHELD
[ ] [ ]
[ ]
----------------------------------------
For all nominees except as noted above
FOR AGAINST ABSTAIN
2. PROPOSAL TO RATIFY THE APPOINTMENT [ ] [ ] [ ]
OF PRICEWATERHOUSECOOPERS LLP AS
INDEPENDENT AUDITORS OF THE COMPANY
FOR THE 1999 FISCAL YEAR
Upon such other matters which may properly come before the
meeting and any adjournment(s) thereof.
MARK HERE FOR ADDRESS CHANGE AND NOTE AT LEFT [ ]
This proxy should be dated, signed by the stockholder(s) exactly as his or her
name appears hereon, and returned promptly in the enclosed envelope. Persons
signing in a fiduciary capacity should so indicate. If shares are held by joint
tenants or as community property, both should sign.
Signature: Date:
-------------------------------- ------------------
Signature: Date:
-------------------------------- ------------------
